Exclusive Summary

• - Fully off-patent with a mature generic market, enabling rapid entry via technology transfer or distribution.
• - Strong anaerobic coverage makes it a guideline-aligned single-agent choice for colorectal/gynecologic surgical prophylaxis and mild-to-moderate cIAI.
• - Addresses large, stable hospital demand: ~313 million surgeries per year globally plus tens of millions of intra-abdominal infection cases.
• - API meets JP/BP/USP/EP/KP, easing multi-region registrations and tenders; reliable supply can capture shortage-driven opportunities.
• - Significant cost advantage versus originator and some combination regimens, supporting wins in tenders and formulary substitutions.